Trastuzumab deruxtecan

Generic Name
Trastuzumab deruxtecan
Brand Names
Enhertu
Drug Type
Biotech
Chemical Formula
-
CAS Number
1826843-81-5
Unique Ingredient Identifier
5384HK7574
Background

Trastuzumab deruxtecan is a HER-2 directed antibody attached to a topoisomerase inhibitor that is approved for use in certain types of metastatic, unresectable breast cancer. It is classified as an antibody-drug conjugate. The cleavable peptide linker used to bind the antibody and drug in this product distinguishes it from other members of its class. Trastuz...

Indication

In the US, trastuzumab deruxtecan is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen either in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. It...

Associated Conditions
Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Adenocarcinoma, Metastatic Breast Cancer, Metastatic Breast Cancer With HER2 Positive, Unresectable Breast Cancer, Locally advanced HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Locally advanced HER2-positive Gastric Adenocarcinoma, Metastatic HER2 Mutant Non-small Cell Lung Cancer, Metastatic HER2-low Breast Cancer, Metastatic HER2-positive Adenocarcinomas of the Gastroesophageal Junction, Metastatic HER2-positive Gastric Adenocarcinoma, Unresectable HER2 Mutant Non-small Cell Lung Cancer, Unresectable HER2-low Breast Cancer, Unresectable HER2/Neu-positive Breast Cancer
Associated Therapies
-

Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

First Posted Date
2022-05-13
Last Posted Date
2024-12-06
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
30
Registration Number
NCT05372614
Locations
🇺🇸

City of Hope Comprehensive Cancer Center, Duarte, California, United States

🇺🇸

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States

🇺🇸

City of Hope at Irvine Lennar, Irvine, California, United States

and more 13 locations

A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC

First Posted Date
2022-02-18
Last Posted Date
2024-12-04
Lead Sponsor
AstraZeneca
Target Recruit Count
72
Registration Number
NCT05246514
Locations
🇨🇳

Research Site, Zhengzhou City, China

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer

First Posted Date
2021-11-09
Last Posted Date
2024-11-08
Lead Sponsor
AstraZeneca
Target Recruit Count
927
Registration Number
NCT05113251
Locations
🇹🇭

Research Site, Khon Kaen, Thailand

A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers

First Posted Date
2021-10-25
Last Posted Date
2022-08-18
Lead Sponsor
Silverback Therapeutics
Target Recruit Count
2
Registration Number
NCT05091528
Locations
🇺🇸

Massachusetts General Hospital, Boston, Massachusetts, United States

Study of T-DXd Monotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma Who Have Received 2 or More Prior Regimens

First Posted Date
2021-08-04
Last Posted Date
2024-11-21
Lead Sponsor
AstraZeneca
Target Recruit Count
95
Registration Number
NCT04989816
Locations
🇨🇳

Research Site, Zhengzhou, China

Scalp Cooling in MBC

First Posted Date
2021-08-03
Last Posted Date
2024-11-07
Lead Sponsor
Dana-Farber Cancer Institute
Target Recruit Count
120
Registration Number
NCT04986579
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)

First Posted Date
2021-03-05
Last Posted Date
2024-12-16
Lead Sponsor
AstraZeneca
Target Recruit Count
1157
Registration Number
NCT04784715
Locations
🇬🇧

Research Site, Taunton, United Kingdom

Phase II Study of T-DX in HER2-positive Breast Cancer Brain Metastases

Phase 2
Completed
Conditions
Interventions
First Posted Date
2021-02-12
Last Posted Date
2023-05-12
Lead Sponsor
Medical University of Vienna
Target Recruit Count
15
Registration Number
NCT04752059
Locations
🇦🇹

AKH Universitaetsklinikum Vienna, Department f. Internal medicine I, oncology, Vienna, Austria

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Phase 3
Active, not recruiting
Conditions
Interventions
First Posted Date
2021-02-05
Last Posted Date
2024-10-23
Lead Sponsor
AstraZeneca
Target Recruit Count
506
Registration Number
NCT04739761
Locations
🇬🇧

Research Site, Edinburgh, United Kingdom

© Copyright 2024. All Rights Reserved by MedPath